263 related articles for article (PubMed ID: 6600187)
1. Inhibition of K and NK lymphocyte cytotoxicity by an inhibitor of adenosine deaminase and deoxyadenosine.
Grever MR; Siaw MF; Coleman MS; Whisler RL; Balcerzak SP
J Immunol; 1983 Jan; 130(1):365-9. PubMed ID: 6600187
[No Abstract] [Full Text] [Related]
2. Mechanism of adenosine triphosphate catabolism induced by deoxyadenosine and by nucleoside analogues in adenosine deaminase-inhibited human erythrocytes.
Bontemps F; Van den Berghe G
Cancer Res; 1989 Sep; 49(18):4983-9. PubMed ID: 2788493
[TBL] [Abstract][Full Text] [Related]
3. Hemolysis in mice treated with deoxycoformycin, an inhibitor of adenosine deaminase.
Smith CM; Belch A; Henderson JF
Biochem Pharmacol; 1980 Apr; 29(8):1209-10. PubMed ID: 6966932
[No Abstract] [Full Text] [Related]
4. Energy metabolism in adenosine deaminase-inhibited human erythrocytes.
Buc HA; Thuillier L; Hamet M; Garreau F; Moncion A; Pérignon JL
Clin Chim Acta; 1986 Apr; 156(1):61-9. PubMed ID: 3486057
[TBL] [Abstract][Full Text] [Related]
5. Effect of 2'-deoxycoformycin infusion on S-adenosylhomocysteine hydrolase and the amount of S-adenosylhomocysteine and related compounds in tissues of mice.
Helland S; Ueland PM
Cancer Res; 1983 Sep; 43(9):4142-7. PubMed ID: 6603264
[TBL] [Abstract][Full Text] [Related]
6. The effects of ADA inhibition on B cell differentiation in the rat.
Barton RW
Adv Exp Med Biol; 1986; 195 Pt A():525-9. PubMed ID: 3524140
[No Abstract] [Full Text] [Related]
7. Effects of 2'-deoxycoformycin on the metabolism of purines and the survival of malignant cells in a patient with T-cell leukemia.
Yu AL; Bakay B; Kung FH; Nyhan WL
Cancer Res; 1981 Jul; 41(7):2677-82. PubMed ID: 6972800
[TBL] [Abstract][Full Text] [Related]
8. Activated T lymphocytes resist the toxic effects of the adenosine deaminase inhibitor, 2-deoxycoformycin.
Kotb M; Veit BC
Cell Immunol; 1982 Sep; 72(1):64-76. PubMed ID: 6983389
[No Abstract] [Full Text] [Related]
9. In vivo inhibition of adenosine deaminase by 2'-deoxycoformycin in mouse blood and leukemia L1210 cells.
Agarwal RP
Biochem Pharmacol; 1980 Feb; 29(2):187-93. PubMed ID: 6965857
[No Abstract] [Full Text] [Related]
10. Deoxyadenosine triphosphate accumulation in erythrocytes of deoxycoformycin-treated mice.
Smith CM; Henderson JF
Biochem Pharmacol; 1982 Apr; 31(8):1545-51. PubMed ID: 6980005
[TBL] [Abstract][Full Text] [Related]
11. 2'-deoxycoformycin toxicity in murine spleen lymphocytes.
Earle MF; Glazer RI
Mol Pharmacol; 1983 Jan; 23(1):165-70. PubMed ID: 6602939
[No Abstract] [Full Text] [Related]
12. Specificity of 2'-deoxycoformycin inhibition of adenosine metabolism in intact human skin fibroblasts.
Holland MJ
Res Commun Chem Pathol Pharmacol; 1986 Mar; 51(3):311-24. PubMed ID: 3486439
[TBL] [Abstract][Full Text] [Related]
13. Effects of deoxyadenosine on the activation of ADA inhibited T & B cells.
Webster AD; Ip H; Pereira S
Clin Exp Immunol; 1982 Dec; 50(3):587-95. PubMed ID: 6299634
[TBL] [Abstract][Full Text] [Related]
14. Production of 2'-deoxycoformycin by the fungus Emericella nidulans and its inhibitory effect on adenosine deaminase.
Kanbe T; Endo A; Hashizume T
Nucleic Acids Symp Ser; 1983; (12):115-8. PubMed ID: 6607458
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of lymphocyte-specific enzymes: a promising approach for selective immunosuppression.
Ruers TJ; Buurman WA; van der Linden CJ; Kootstra G
Transplant Proc; 1987 Feb; 19(1 Pt 2):1287-9. PubMed ID: 3274319
[No Abstract] [Full Text] [Related]
16. Biochemical basis of the increased activity of 9-beta-D-arabinofuranosyladenine in the presence of inhibitors of adenosine deaminase.
Plunkett W; Alexander L; Chubb S; Loo TL
Cancer Res; 1979 Sep; 39(9):3655-60. PubMed ID: 476690
[No Abstract] [Full Text] [Related]
17. Potential use of purine nucleosides and enzyme inhibitors for selective depletion of Thy-lymphoblasts from human bone marrow.
Russell NH; Hoffbrand AV; Bellingham AJ
Leuk Res; 1986; 10(3):325-9. PubMed ID: 3081767
[TBL] [Abstract][Full Text] [Related]
18. Immune function in mice exposed to the adenosine deaminase inhibitor 2'-deoxycoformycin during immune system development.
Luebke RW; Lawson LD; Rogers RR; Riddle MM; Smialowicz RJ
Immunopharmacol Immunotoxicol; 1987; 9(2-3):149-61. PubMed ID: 3501794
[TBL] [Abstract][Full Text] [Related]
19. Purinogenic lymphocytotoxicity: clues to a wider chemotherapeutic potential for the adenosine deaminase inhibitors.
Kefford RF; Fox RM
Cancer Chemother Pharmacol; 1983; 10(2):73-8. PubMed ID: 6600985
[No Abstract] [Full Text] [Related]
20. Metabolic abnormalities of human adenosine deaminase deficiency reproduced in the mouse by 2'-deoxycoformycin, and adenosine deaminase inhibitor.
Ratech H; Thorbecke GJ; Hirschhorn R
Clin Immunol Immunopathol; 1981 Oct; 21(1):119-27. PubMed ID: 6268339
[No Abstract] [Full Text] [Related]
[Next] [New Search]
